Showing 5171-5180 of 10638 results for "".
Challenges in Treating Polycystic Ovarian Syndrome
https://reachmd.com/programs/advances-in-womens-health/challenges-in-treating-polycystic-ovarian-syndrome/1879/Anovulation is a significant challenge for reproductive age women. The most common endocrinologic cause of this is PCOS. With the help of Dr. Sam Thatcher, pioneer in IVF technology and director of the Center for Applied Reproductive Science, we explore the exciting new possibilities and not-so-newAdvancing Long-Term Outcomes in Systemic Mastocytosis: The Latest Research
https://reachmd.com/programs/clinicians-roundtable/systemic-mastocytosis-long-term-outcomes-research/50988/Long-term disease control is emerging as a new benchmark in systemic mastocytosis, but what’s driving this shift in care? Find out as Dr. Charles Turck speaks with Dr. Anthony Hunter about the latest research shaping treatment decisions, including the durability of KIT-targeted therapies and strategUnlocking the Potential of TYK2 Inhibitors in Plaque Psoriasis
https://reachmd.com/programs/frontlines-psoriasis/tyk2-inhibitors-plaque-psoriasis-potential/39952/With high selectivity, durable response, and once-daily dosing, next-generation TYK2 inhibitors offer a promising oral option for patients with moderate-to-severe plaque psoriasis. Ryan Quigley sits down with Dr. Christopher Bunick, Associate Professor of Dermatology and Translational BiomedPREVENT vs PCE: Refining ASCVD Risk Prediction in Statin-Treated Populations
https://reachmd.com/programs/heart-matters/prevent-vs-pce-refining-ascvd-risk-prediction-in-statin-treated-populations/37198/Prognostic Value of Red Cell Distribution Width at Ruxolitinib Initiation in Myelofibrosis
https://reachmd.com/programs/project-oncology/prognostic-value-of-red-cell-distribution-width-at-ruxolitinib-initiation-in-myelofibrosis/37207/The Role of the Complement System in Kidney Diseases
https://reachmd.com/programs/cme/the-role-of-the-complement-system-in-kidney-diseases/35706/The Role of the Complement System in Kidney DiseasesOptimizing NSCLC Care: Advances in Lung Biopsy and Biomarker Testing
https://reachmd.com/programs/deep-breaths-updates-chest/program-name/35980/Cutting-edge biopsy methods and streamlined biomarker testing are transforming early-stage non-small cell lung cancer (NSCLC) care. Hear from Drs. Gerard Silvestri, Fabien Maldonado, and Adam Fox as they discuss the evolution of bronchoscopic techniques, insights from landmark trials, and the role oInitiating Colorectal Cancer Screening Earlier: A Look at the Evidence
https://reachmd.com/programs/clinicians-roundtable/initiating-colorectal-cancer-screening-earlier-a-look-at-the-evidence/36540/In light of guidelines for the starting age of colorectal cancer screening shifting, a recent study explored how screening outcomes compare in adults age 45 to 49 and adults over 50. Across metrics like initiation, adherence, adenoma detection, and colonoscopy yield, the evidence shows support for eNew-Onset Ketosis-Prone Diabetes in an Adult with Spinal Muscular Atrophy Type III
https://reachmd.com/programs/neurofrontiers/new-onset-ketosis-prone-diabetes-in-an-adult-with-spinal-muscular-atrophy-type-iii/36615/ADT Monotherapy for mHSPC: How to Identify the Right Patients
https://reachmd.com/programs/frontlines-prostate-cancer/adt-monotherapy-for-mhspc-how-to-identify-the-right-patients/32219/While initial evidence favors combination regimens for metastatic hormone-sensitive prostate cancer (mHSPC), findings suggest that approximately 20 percent of patients may still benefit from ADT alone, particularly those with indolent disease features such as low-volume metastases or favorable PSA k